Published: Sep 29, 2021
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 /PRNewswire/ — Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer. The data demonstrated the potential of extending Freenome’s multiomics approach into other cancers, such as pancreatic cancer, with biomarkers already embedded in the existing platform.
Freenome’s platform uses a routine blood test to detect cancer.
“An accurate blood-based test like this could be a powerful tool for early diagnosis and treatment, impacting so many patients,” said Randall Brand, M.D., professor of Medicine and Human Genetics at the University of Pittsburgh School of Medicine, and co-author of the study. “We are hoping to further validate the findings through additional studies, which are already underway.”
Pancreatic cancer is one of the deadliest cancers, with an overall five-year survival rate of 11%. If detected at an early stage, the five-year survival rate increases to 42%. The only FDA-authorized test for pancreatic cancer is the carbohydrate antigen 19-9 (CA19-9), which is only cleared for monitoring response to therapy.
This retrospective study of 75 participants evaluated whether Freenome’s multiomics approach of combining methylation and CA19-9 signals together (as a subset of existing analytes in the platform) detected pancreatic cancer in stages II, III and IV with higher sensitivity than either alone.
Across all stages studied, Freenome’s approach achieved a sensitivity of 93% at a nominal specificity of 96%. At an identical specificity, the sensitivity of methylation or CA19-9 alone was 74% and 87%, respectively. In stages II, III and IV, the multiomics approach achieved a sensitivity of 82%, 89%, and 100%, respectively.
This new study demonstrates that Freenome’s platform can be used to detect pancreatic cancer in addition to colorectal cancer (CRC). Last year, Freenome presented data showing a sensitivity of 94% at a specificity of 94% for early-stage (I/II) CRC using their multiomics platform. Freenome’s CRC test is currently undergoing analytical and clinical validation.
“We’re demonstrating success in detecting CRC and advanced adenomas in blood. We’re now expanding our platform to detect additional cancers,” said Mike Nolan, chief executive officer, Freenome. “Our goal is to transform the way cancer of all types is managed by enabling early detection, and this data on pancreatic cancer is an important step in that direction.”
Freenome is a biotechnology company with the most comprehensive multiomics platform for early cancer detection using a routine blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is headquartered in South San Francisco, California.
 National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER) July 9, 2021.
Girish Putcha, Tzu-Yu Liu, Eric Ariazi, Marvin Bertin, Adam Drake, Michael Dzamba, Greg Hogan, Steven Kothen-Hill, Jeffrey Liao, Kang Li, Shivani Mahajan, Krishnan K. Palaniappan, Poonam Sansanwal, John St. John, Peter Ulz, Nathan Wan, Hayley Warsinske, David Weinberg, Rui Yang and C. Jimmy Lin. Blood-Based Detection of Early-Stage Colorectal Cancer Using Multiomics and Machine Learning. Poster presented at: American Society of Clinical Oncology, Gastroenterology Symposium; January 2020.
SOURCE Freenome Holdings, Inc.
CLICK HERE FOR MORE CLINICAL NEWS
CLICK HERE FOR MORE TECHNOLOGY NEWS
Apply to our open positions: